# Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206)

> **NCT03865082** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Idera Pharmaceuticals, Inc.** · enrollment: 30 (estimated)

## Conditions studied

- Solid Tumor

## Interventions

- **DRUG:** Tilsotolimod
- **DRUG:** Nivolumab
- **DRUG:** Ipilimumab

## Key facts

- **NCT ID:** NCT03865082
- **Lead sponsor:** Idera Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-10-29
- **Primary completion:** 2022-03
- **Final completion:** 2022-04
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2022-02-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03865082

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03865082, "Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03865082. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*